Definition
The role of antiretroviral treatment (ART) in pregnant and breastfeeding women for prevention of mother-to-child transmission (pMTCT) of HIV has become simple: control of maternal HIV viremia with highly active combination ART effectively blocks MTCT. Details, however, are complex. Lifetime optimal health for mother and child must be balanced with potential toxicities associated with such treatment. The pharmacokinetics of ART in pregnancy and transfer of ART through the placenta and in breast milk are also important considerations in optimizing the health of mother and infant. Management of opportunistic infections in the setting of pregnancy, and limitations in access to, and lack of safety data for newer combination therapies also impact the complexity of managing HIV in pregnancy. ART as preexposure prophylaxis (PreP) for serodiscordant couples planning pregnancies and the use of PreP in serodiscordant couples during pregnancy and breastfeeding have emerged as strategies...
References
Advisory Committee Consensus. Antiretroviral Pregnancy Registry international interim report. Wilmington: INC Research, LLC; 2015.
Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry international interim report for 1 January 1989 through 31 January 2015. Wilmington: Registry Coordinating Center; 2015. www.APRegistry.com. Accessed 14 Sept 2015.
Arrivé E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, Masquelier B, Leroy V, Perre PV, Rouzioux C, Dabis F, Ghent Group on HIV in Women and Children. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol. 2007;36(5):1009–21. Epub 28 May 2007.
Buckoreelall K, Cressey TR, King JR. Pharmacokinetic optimization of antiretroviral therapy in pregnancy. Clin Pharmacokinet. 2012;51:639–59.
Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331(18):1173–80.
Ford N, Mofenson L, Shubber A, Calmy A, Andrieux-Meyer I, Vitoria M, Shaffer N, Renaud F. Safety of Efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS. 2014;28 Suppl 2:S123–31.
Gilbert EM, Darin KM, Scarsi KK, McLaughlin MM. Antiretroviral pharmacokinetics in pregnant women. Pharmacotherapy. 2015;35(9):838–55.
Jamieson DJ, Chasela CS, Hudgens MG, et al. Maternal and infant antiretroviral regimens to prevent postnatal HIV1 transmission: 48-week follow-up of the BAN randomised controlled trial. Lancet. 2012;379(9835):2449–58.
Katz IT, Shapiro R, Li D, Govindarajulu U, Thompson B, Watts DH, Hughes MD, Tuomala R. Risk factors for detectable HIV-1 RNA at delivery among women receiving highly active antiretroviral therapy in the women and infants transmission study. J Acquir Immune Defic Syndr. 2010;54(1):27–34.
McCormack SA, Best BM. Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals. Clin Pharmacokinet. 2014;53:989–1004.
McIlleron H, Abdel-Rahman S, Dave JA, Blockman M, Owen A. Special populations and pharmacogenetic issues in tuberculosis drug development and clinical research. J Infect Dis. 2015;211 Suppl 3:S115–25.
Mofenson LM. Antiretroviral therapy and adverse pregnancy outcome: the elephant in the room? J Infect Dis. 2015;pii:jiv390. [Epub ahead of print].
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services 2015. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 14 Sept 2015.
Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Accessed 14 Sept 2015.
Sibiude J, Mandelbrot L, Blanche S, et al. Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11). PLoS Med/Public Libr Sci. 2014;11(4):e1001635.
World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infections. 2013. http://www.who.int/hiv/pub/guidelines/arv2013/download/en/index.html
World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015. ISBN 978 92 4 150956 5 (NLM classification: WC 503.2).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this entry
Cite this entry
Vogler, M., Beckerman, K. (2015). Prevention of Mother-to-Child Transmission of AIDS. In: Hope, T., Stevenson, M., Richman, D. (eds) Encyclopedia of AIDS. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9610-6_449-1
Download citation
DOI: https://doi.org/10.1007/978-1-4614-9610-6_449-1
Received:
Accepted:
Published:
Publisher Name: Springer, New York, NY
Online ISBN: 978-1-4614-9610-6
eBook Packages: Springer Reference MedicineReference Module Medicine